Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CINGNASDAQ:HOOKNASDAQ:LGVNNASDAQ:XBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$4.51+7.4%$4.05$1.80▼$20.83$19.15M-0.851.10 million shs149,999 shsHOOKHookipa Pharma$1.48+4.2%$1.24$0.72▼$7.55$18.04M0.9682,003 shs75,192 shsLGVNLongeveron$1.29-0.8%$1.41$1.14▼$6.40$19.26M0.221.50 million shs101,317 shsXBIOXenetic Biosciences$2.79-7.3%$2.85$2.20▼$5.20$4.30M2.2813,515 shs16,270 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate0.00%-3.67%+9.95%+13.51%+535.30%HOOKHookipa Pharma0.00%-8.97%-8.97%+19.33%-80.90%LGVNLongeveron0.00%+5.69%-8.45%-24.42%-59.25%XBIOXenetic Biosciences0.00%+1.14%+6.87%-15.26%-19.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCINGCingulate2.2805 of 5 stars3.52.00.00.03.10.80.6HOOKHookipa Pharma3.1395 of 5 stars3.25.00.00.03.31.70.6LGVNLongeveron3.4995 of 5 stars3.65.00.00.02.01.71.3XBIOXenetic Biosciences1.9626 of 5 stars0.05.00.00.03.30.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCINGCingulate 3.00Buy$26.00476.50% UpsideHOOKHookipa Pharma 2.33Hold$4.50204.05% UpsideLGVNLongeveron 3.25Buy$8.67571.83% UpsideXBIOXenetic Biosciences 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest XBIO, CING, HOOK, and LGVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.005/19/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $11.004/21/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.004/9/2025XBIOXenetic BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/21/2025LGVNLongeveronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/20/2025XBIOXenetic BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCINGCingulateN/AN/AN/AN/A($70.63) per shareN/AHOOKHookipa Pharma$9.35M1.93N/AN/A$9.08 per share0.16LGVNLongeveron$2.23M8.65N/AN/A$2.68 per share0.48XBIOXenetic Biosciences$2.58M1.67N/AN/A$6.36 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCINGCingulate-$23.53M-$8.48N/AN/AN/AN/A-570.20%-236.15%8/12/2025 (Estimated)HOOKHookipa Pharma-$81.58M-$5.85N/AN/AN/A-86.74%-33.31%-21.65%8/6/2025 (Estimated)LGVNLongeveron-$21.41M-$6.28N/AN/AN/A-967.49%-142.43%-100.84%8/13/2025 (Estimated)XBIOXenetic Biosciences-$4.14M-$2.38N/AN/AN/A-161.63%-49.51%-43.99%8/12/2025 (Estimated)Latest XBIO, CING, HOOK, and LGVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HOOKHookipa Pharma-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A5/13/2025Q1 2025XBIOXenetic Biosciences-$0.72-$0.59+$0.13-$0.59$0.52 million$0.59 million5/8/2025Q1 2025CINGCingulate-$1.00-$1.04-$0.04-$1.04N/AN/A3/18/2025Q4 2024XBIOXenetic Biosciences-$0.20-$0.68-$0.48-$0.68$0.18 million$0.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCINGCingulateN/AN/AN/AN/AN/AHOOKHookipa PharmaN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCINGCingulateN/A7.357.35HOOKHookipa PharmaN/A3.263.26LGVNLongeveronN/A7.677.67XBIOXenetic BiosciencesN/A6.976.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCINGCingulate41.31%HOOKHookipa Pharma63.88%LGVNLongeveron10.01%XBIOXenetic Biosciences15.12%Insider OwnershipCompanyInsider OwnershipCINGCingulate5.27%HOOKHookipa Pharma3.30%LGVNLongeveron11.20%XBIOXenetic Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCINGCingulate204.25 million2.66 millionNot OptionableHOOKHookipa Pharma5612.19 million11.66 millionOptionableLGVNLongeveron2014.93 million12.00 millionNot OptionableXBIOXenetic Biosciences41.54 million1.32 millionNot OptionableXBIO, CING, HOOK, and LGVN HeadlinesRecent News About These CompaniesXenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | accessnewswire.comXenetic Biosciences (XBIO) Receives a Hold from H.C. WainwrightApril 10, 2025 | markets.businessinsider.comXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentApril 9, 2025 | accessnewswire.comXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentApril 9, 2025 | accessnewswire.comXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing SarcomaMarch 26, 2025 | accessnewswire.comXenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 20, 2025 | finance.yahoo.comXenetic Biosciences, Inc. Reports Full Year 2024 Financial ResultsMarch 19, 2025 | accessnewswire.comXenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic ResponsesMarch 13, 2025 | accessnewswire.comXenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy MeetingFebruary 27, 2025 | accessnewswire.comXenetic Biosciences extends research agreement with University of Virginia for the advancement of its DNase-based oncology platformDecember 18, 2024 | pharmabiz.comXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentDecember 17, 2024 | accesswire.comXenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology PlatformDecember 16, 2024 | accesswire.comXenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology ProgramDecember 5, 2024 | accesswire.comXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentNovember 22, 2024 | accesswire.comXenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung MetastasisNovember 21, 2024 | accesswire.comXenetic Biosciences, Inc. Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | accesswire.comXenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma ModelsNovember 12, 2024 | accesswire.comXenetic Biosciences Extends Drug Development Pact With Scripps Research InstituteNovember 9, 2024 | precisionmedicineonline.comXenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformNovember 7, 2024 | accesswire.comXenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024October 22, 2024 | accesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher's Midnight Air Taxi Soars, But Stock Doesn’t BudgeBy Jeffrey Neal Johnson | June 4, 2025View Archer's Midnight Air Taxi Soars, But Stock Doesn’t BudgeHims & Hers Stock: Buy the Dip or Wait It Out?By Gabriel Osorio-Mazilli | June 5, 2025View Hims & Hers Stock: Buy the Dip or Wait It Out?Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?By Jeffrey Neal Johnson | June 8, 2025View Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?Is Lululemon’s 18% Selloff Overdone? Analysts Say YesBy Gabriel Osorio-Mazilli | June 9, 2025View Is Lululemon’s 18% Selloff Overdone? Analysts Say YesAppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayBy Leo Miller | June 10, 2025View AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayXBIO, CING, HOOK, and LGVN Company DescriptionsCingulate NASDAQ:CING$4.51 +0.31 (+7.38%) Closing price 04:00 PM EasternExtended Trading$4.72 +0.22 (+4.77%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Hookipa Pharma NASDAQ:HOOK$1.48 +0.06 (+4.23%) Closing price 04:00 PM EasternExtended Trading$1.46 -0.01 (-1.01%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Longeveron NASDAQ:LGVN$1.29 -0.01 (-0.77%) Closing price 04:00 PM EasternExtended Trading$1.32 +0.03 (+2.33%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Xenetic Biosciences NASDAQ:XBIO$2.79 -0.22 (-7.31%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore SoundHound’s AI Growth Story Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.